Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Breast 1

Conditions

Neuroendocrine Tumors 2Neuroblastoma 2Meningioma 2Medulloblastoma 2Small Cell Lung Carcinoma 1Recurrence 1Lymphoma, Mantle-Cell 1Lung Neoplasms 1Breast Neoplasms, Male 1Breast Neoplasms 1

Interventions

Cyclophosphamide 17Trastuzumab 16Paclitaxel 15Doxorubicin 11Docetaxel 10Radiotherapy 9Carboplatin 9Capecitabine 9Bevacizumab 8Lapatinib 7Taxes 6Tamoxifen 6Gemcitabine 5Filgrastim 5Chemotherapy, Adjuvant 5sargramostim 4Sorafenib 4Radiation 4Neoadjuvant Therapy 4Granulocyte-Macrophage Colony-Stimulating Factor 4Vinorelbine 3Thiotepa 3Peripheral Blood Stem Cell Transplantation 3Melphalan 3Irinotecan 3Immunohistochemistry 3Granulocyte Colony-Stimulating Factor 3Erlotinib Hydrochloride 3Anastrozole 3Albumin-Bound Paclitaxel 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Breast Neoplasms, Male × 90Y-octreotide, DOTA-Tyr(3)- × Clear all
NCT00006370 2013-05-01

Radiolabeled SMT-487 (Yttrium Y 90-DOTA-tyr3-octreotide) in Treating Patients With Refractory Small Cell Lung Cancer or Metastatic Breast Cancer

Novartis

Phase 2 Completed
275 enrolled
BreastThoracic

Breast Neoplasms, Lung Neoplasms, Breast Neoplasms, Male, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡